SAR-096: A phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).

Sujana Movva,Margaret von Mehren,Elizabeth Handorf,Jeffrey A. Morgan,Michael Nathenson,Katherine Thornton,Eric Daniel Tetzlaff,Emma Barker,Linda Thibodeau,Allisa Cherae Harley,April King,Rosanna Veggeberg,Juliet A. Leshner,Lori Rink,Suzanne George

SAR-096: A phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).

2020

Sujana Movva
Margaret von Mehren
Elizabeth Handorf
Jeffrey A. Morgan
Michael Nathenson
Katherine Thornton
Eric Daniel Tetzlaff
Emma Barker
Linda Thibodeau
Allisa Cherae Harley
April King
Rosanna Veggeberg
Juliet A. Leshner
Lori Rink
Suzanne George

11544Background: Inhibition of CDK4 is being studied in a variety of sarcomas, especially dedifferentiated liposarcoma (DDL) where prolonged progression free survival has been noted. Exposure to CD...

Keywords:

Oncology
Everolimus
Dedifferentiated liposarcoma
Leiomyosarcoma
Internal medicine
Pathology
Ribociclib
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations